13F-HR filed by SAMSARA BIOCAPITAL, LLC
SAMSARA BIOCAPITAL, LLC filed this 13F-HR for the quarter ended 2018-12-31, filed 2019-02-14, with 17 holding rows worth $104,184,000.
- Accession
- 0001104659-19-008738
- Filer
- CIK 1744967
- Filed
- 2019-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2018
A holdings report, 17 entries on the cover page, a total value of $104,184,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $104,187,000 with VALUE read as thousands by filing date, 13F file number 028-19375. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ALLAKOS INC | 01671P100 | COM | 458,366 | $23,959,000 | thousands by filing date | |
| INTERCEPT PHARMACEUTICALS IN | 45845P108 | COM | 234,375 | $23,623,000 | thousands by filing date | |
| PRINCIPIA BIOPHARMA INC | 74257L108 | COM | 383,480 | $10,504,000 | thousands by filing date | |
| SUTRO BIOPHARMA INC | 869367102 | COM | 1,125,576 | $10,153,000 | thousands by filing date | |
| ODONATE THERAPEUTICS INC | 676079106 | COM | 595,850 | $8,390,000 | thousands by filing date | |
| LIQUIDIA CORPORATION COM NEW | 53635D202 | Stock | 378,420 | $8,197,000 | thousands by filing date | |
| SYROS PHARMACEUTICALS INC | 87184Q107 | COM | 1,059,938 | $5,904,000 | thousands by filing date | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 150,000 | $2,963,000 | thousands by filing date | |
| EVELO BIOSCIENCES INC | 299734103 | COM | 227,529 | $2,960,000 | thousands by filing date | |
| MIRAGEN THERAPEUTICS INC | 60463E103 | COM | 909,090 | $2,755,000 | thousands by filing date | |
| Aravive Inc | 03890D108 | Common / Ordinary Stock | 442,733 | $1,558,000 | thousands by filing date | |
| CATABASIS PHARMACEUTICALS IN | 14875P206 | COM NEW | 300,000 | $1,311,000 | thousands by filing date | |
| UROVANT SCIENCES | G9381B108 | COMMON STOCK | 157,480 | $1,038,000 | thousands by filing date | |
| MILLENDO THERAPEUTICS INC | 60040X103 | COM | 45,101 | $359,000 | thousands by filing date | |
| SURFACE ONCOLOGY INC | 86877M209 | COM | 78,300 | $332,000 | thousands by filing date | |
| TRILLIUM THERAPEUTICS INC COM NEW | 89620X506 | Stock | 71,619 | $122,000 | thousands by filing date | |
| EDGE THERAPEUTICS INC | 279870109 | COM | 183,332 | $59,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-19-008738 | this filing | 2019-02-14 | acceptance time not in the bulk data set |